Andere Sprachen PAVmed Inc.

Aktien

A3E2MX

US70387R4039

PAVM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 02.05.2024			% 5 Tage	% 1. Jan.
2,24 ^USD	-3,03 %		+26,55 %	-45,63 %

27.03.	Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024
25.03.	PAVmed Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024	14:36
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024	02.05.
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	30.04.
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month	29.04.
PAVmed : Material Agreement - Form 8-K	26.04.
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	08.04.
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	21.03.
PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	21.03.
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference	20.03.
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024	13.03.
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024	12.03.
PAVmed : Failure to Satisfy Listing Rule - Form 8-K	08.03.
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program	19.02.
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program	16.02.
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony	15.02.
Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors	09.02.
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors	08.02.
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	12.12.
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders	11.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PAVmed Inc.

Aktien

A3E2MX

US70387R4039

PAVM

Andere Sprachen

Filter